数据之源，洞见之始

MAPK family signaling cascades

Klann K, Bojkova D, Tascher G, Ciesek S, Münch C, Cinatl J. Growth Factor Receptor Signaling Inhibition Prevents SARS-CoV-2 Replication. Molecular Cell. 2020 Oct;80(1):164–174.e4. doi: 10.1016/j.molcel.2020.08.006.; Hampton SE, Dore TM, Schmidt WK. Rce1: mechanism and inhibition. Critical Reviews in Biochemistry and Molecular Biology. 2018 Feb 09;53(2):157–74. doi: 10.1080/10409238.2018.1431606.; Ahearn I, Zhou M, Philips MR. Posttranslational Modifications of RAS Proteins. Cold Spring Harb Perspect Med. 2018 Jan 08;8(11):a031484. doi: 10.1101/cshperspect.a031484.; Dharmaiah S, Bindu L, Tran TH, Gillette WK, Frank PH, Ghirlando R, Nissley DV, Esposito D, McCormick F, Stephen AG, Simanshu DK. Structural basis of recognition of farnesylated and methylated KRAS4b by PDEd. Proc Natl Acad Sci U S A. 2016 Nov 01;113(44):E6766–75. PMID: 27791178; PMCID: PMC5098621.; Lu S, Jang H, Gu S, Zhang J, Nussinov R. Drugging Ras GTPase: a comprehensive mechanistic and signaling structural view. Chem Soc Rev. 2016 Sep 21;45(18):4929–52. PMID: 27396271; PMCID: PMC5021603.; Kyriakis JM, Avruch J. Mammalian MAPK signal transduction pathways activated by stress and inflammation: a 10-year update. Physiol Rev. 2012 Apr;92(2):689–737. doi: 10.1152/physrev.00028.2011. PMID: 22535895.; Plotnikov A, Zehorai E, Procaccia S, Seger R. The MAPK cascades: Signaling components, nuclear roles and mechanisms of nuclear translocation. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 2011 Sep;1813(9):1619–33. doi: 10.1016/j.bbamcr.2010.12.012.; Gysin S, Salt M, Young A, McCormick F. Therapeutic Strategies for Targeting Ras Proteins. Genes & Cancer. 2011 Mar 01;2(3):359–72. doi: 10.1177/1947601911412376.; Cargnello M, Roux PP. Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiol Mol Biol Rev. 2011 Mar;75(1):50–83. PMID: 21372320; PMCID: PMC3063353.; Burrows JF, Kelvin AA, McFarlane C, Burden RE, McGrattan MJ, De la Vega M, Govender U, Quinn DJ, Dib K, Gadina M, Scott CJ, Johnston JA. USP17 Regulates Ras Activation and Cell Proliferation by Blocking RCE1 Activity. Journal of Biological Chemistry. 2009 Apr;284(14):9587–95. doi: 10.1074/jbc.m807216200.; Coulombe P, Meloche S. Atypical mitogen-activated protein kinases: Structure, regulation and functions. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 2007 Aug;1773(8):1376–87. doi: 10.1016/j.bbamcr.2006.11.001.; Michaelson D, Ali W, Chiu VK, Bergo M, Silletti J, Wright L, Young SG, Philips M. Postprenylation CAAX processing is required for proper localization of Ras but not Rho GTPases. Mol Biol Cell. 2005 Apr;16(4):1606–16. PMID: 15659645; PMCID: PMC1073645.; Scott Reid T, Terry KL, Casey PJ, Beese LS. Crystallographic Analysis of CaaX Prenyltransferases Complexed with Substrates Defines Rules of Protein Substrate Selectivity. Journal of Molecular Biology. 2004 Oct;343(2):417–33. doi: 10.1016/j.jmb.2004.08.056.; Aiyagari AL, Taylor BR, Aurora V, Young SG, Shannon KM. Hematologic effects of inactivating the Ras processing enzyme Rce1. Blood. 2003 Mar 15;101(6):2250–2. doi: 10.1182/blood-2002-07-2250. PMID: 12433685.; Bergo MO, Ambroziak P, Gregory C, George A, Otto JC, Kim E, Nagase H, Casey PJ, Balmain A, Young SG. Absence of the CAAX Endoprotease Rce1: Effects on Cell Growth and Transformation. Molecular and Cellular Biology. 2002 Jan 01;22(1):171–81. doi: 10.1128/mcb.22.1.171-181.2002.; Ashar HR, James L, Gray K, Carr D, McGuirk M, Maxwell E, Black S, Armstrong L, Doll RJ, Taveras AG, Bishop WR, Kirschmeier P. The farnesyl transferase inhibitor SCH 66336 induces a G(2) --> M or G(1) pause in sensitive human tumor cell lines. Exp Cell Res. 2001 Jan 01;262(1):17–27. doi: 10.1006/excr.2000.5076. PMID: 11120601.; End DW, Smets G, Todd AV, Applegate TL, Fuery CJ, Angibaud P, Venet M, Sanz G, Poignet H, Skrzat S, Devine A, Wouters W, Bowden C. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res. 2001 Jan 01;61(1):131–7. PMID: 11196150.; Hollander I, Frommer E, Mallon R. Human ras-converting enzyme (hRCE1) endoproteolytic activity on K-ras-derived peptides. Anal Biochem. 2000 Nov 01;286(1):129–37. doi: 10.1006/abio.2000.4795. PMID: 11038283.; CHEN Y. Selective Inhibition of ras-Transformed Cell Growth by a Novel Fatty Acid-Based Chloromethyl Ketone Designed to Target Ras Endoprotease. Annals of the New York Academy of Sciences. 1999 Dec;886(1):103–8. doi: 10.1111/j.1749-6632.1999.tb09405.x.; Otto JC, Kim E, Young SG, Casey PJ. Cloning and Characterization of a Mammalian Prenyl Protein-specific Protease. Journal of Biological Chemistry. 1999 Mar;274(13):8379–82. doi: 10.1074/jbc.274.13.8379.; Kim E, Ambroziak P, Otto JC, Taylor B, Ashby M, Shannon K, Casey PJ, Young SG. Disruption of the Mouse Rce1 Gene Results in Defective Ras Processing and Mislocalization of Ras within Cells. Journal of Biological Chemistry. 1999 Mar;274(13):8383–90. doi: 10.1074/jbc.274.13.8383.; Liu M, Bryant MS, Chen J, Lee S, Yaremko B, Lipari P, Malkowski M, Ferrari E, Nielsen L, Prioli N, Dell J, Sinha D, Syed J, Korfmacher WA, Nomeir AA, Lin CC, Wang L, Taveras AG, Doll RJ, Njoroge FG, Mallams AK, Remiszewski S, Catino JJ, Girijavallabhan VM, Bishop WR. Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice. Cancer Res. 1998 Nov 01;58(21):4947–56. PMID: 9810004.; Njoroge FG, Taveras AG, Kelly J, Remiszewski S, Mallams AK, Wolin R, Afonso A, Cooper AB, Rane DF, Liu Y, Wong J, Vibulbhan B, Pinto P, Deskus J, Alvarez CS, del Rosario J, Connolly M, Wang J, Desai J, Rossman RR, Bishop WR, Patton R, Wang L, Kirschmeier P, Bryant MS, Nomeir AA, Lin C-, Liu M, McPhail AT, Doll RJ, Girijavallabhan VM, Ganguly AK. (+)-4-[2-[4-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]- pyridin-11(R)-yl)-1-piperidinyl]-2-oxo-ethyl]-1-piperidinecarboxamide (SCH-66336): A Very Potent Farnesyl Protein Transferase Inhibitor as a Novel Antitumor Agent. J. Med. Chem. 1998 Oct 30;41(24):4890–902. doi: 10.1021/jm980462b.; Chen Y. Inhibition of K-ras-transformed rodent and human cancer cell growth via induction of apoptosis by irreversible inhibitors of ras endoprotease1This work was presented in part at the 1997 meeting on Biology of Proteolysis, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA, 23–27 April 1997.1. Cancer Letters. 1998 Sep;131(2):191–200. doi: 10.1016/s0304-3835(98)00146-3.; Casey PJ, Solski PA, Der CJ, Buss JE. p21ras is modified by a farnesyl isoprenoid. Proc. Natl. Acad. Sci. U.S.A. 1989 Nov;86(21):8323–7. doi: 10.1073/pnas.86.21.8323.